keyword
https://read.qxmd.com/read/38635113/dapagliflozin-and-empagliflozin-in-paediatric-indications-a-systematic-review
#1
Sebastiano A G Lava, Craig Laurence, Alessandro Di Deo, Nicole Sekarski, Michael Burch, Oscar Della Pasqua
INTRODUCTION: In adults, sodium-glucose cotransporter type 2 inhibitors have revolutionised the treatment of type 2 diabetes mellitus, heart failure, and chronic kidney disease. OBJECTIVE: We aimed to review information on compassionate use, clinical pharmacology, efficacy, and safety of dapagliflozin and empagliflozin in children. METHODS: We conducted a systematic review of published clinical trials, case reports, and observational studies in Medline, Excerpta Medica, and Web of Science databases from inception to September 2023...
April 18, 2024: Paediatric Drugs
https://read.qxmd.com/read/38634983/safety-of-linagliptin-in-patients-with-type-2-diabetes-mellitus-a-systematic-review-and-meta-analysis-of-randomized-clinical-trials
#2
REVIEW
Hadir Aljohani, Fares S Alrubaish, Waad M Alghamdi, Fawaz Al-Harbi
BACKGROUND: Linagliptin is an oral dipeptidyl peptidase DPP-4 inhibitor, which is indicated for the treatment of Type 2 diabetes mellitus (T2DM) as monotherapy or add-on to therapy with other hypoglycemic drugs. OBJECTIVES: We aimed to summarize the evidence from randomized controlled trials (RCTs) to assess the safety of linagliptin focusing on cardiovascular risks among subjects with type 2 diabetes mellitus. METHODS: We conducted a systematic search across the following databases: Medline, Embase, the Cochrane Central Register of Controlled Trials and ClinicalTrials...
April 18, 2024: Therapeutic Innovation & Regulatory Science
https://read.qxmd.com/read/38632609/the-efficacy-of-minimally-invasive-coronary-artery-bypass-grafting-mics-cabg-for-patients-with-coronary-artery-diseases-and-diabetes-a-single-center-retrospective-study
#3
JOURNAL ARTICLE
Zhao Guangxin, Chi Liqun, Liang Lin, Liu Jiaji, Ma Xiaolong, Zhang Yuxiao, Huang Qiuyue, Kong Qingyu
BACKGROUND: conventional coronary artery bypass grafting (CCABG) tends to cause severe complications in patients with comorbid Coronary Artery Diseases (CAD) and diabetes. On the other hand, the Minimally Invasive Cardiac Surgery Coronary Artery Bypass Grafting (MICS CABG) via transthoracic incision is associated with rapid recovery and reduced complications. Adding to the limited literature, this study compares CCABG and MICS CABG in terms of efficacy and safety. METHODS: Herein, 104 CCABG and MICS CABG cases (52 cases each) were included...
April 18, 2024: Journal of Cardiothoracic Surgery
https://read.qxmd.com/read/38632048/glucagon-like-peptide-1-receptor-agonists-use-and-associations-with-outcomes-in-heart-failure-and-type-2-diabetes-data-from-the-swedish-heart-failure-and-swedish-national-diabetes-registries
#4
JOURNAL ARTICLE
Markus Wallner, Mattia Emanuele Biber, Davide Stolfo, Gianfranco Sinagra, Lina Benson, Ulf Dahlström, Soffia Gudbjörnsdottir, Francesco Cosentino, Peter G M Mol, Giuseppe M C Rosano, Javed Butler, Marco Metra, Lars H Lund, Giulia Ferrannini, Gianluigi Savarese
AIMS: To assess use and associations with outcomes of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in a real-world population with heart failure (HF) and type 2 diabetes (T2DM). METHODS AND RESULTS: The Swedish HF Registry was linked with the National Diabetes Registry and other national registries. Independent predictors of GLP-1 RA use were assessed by multivariable logistic regressions, and associations with outcomes by Cox regressions in a 1:1 propensity score-matched cohort...
April 17, 2024: European Heart Journal. Cardiovascular Pharmacotherapy
https://read.qxmd.com/read/38629871/effects-safety-and-treatment-experience-of-advanced-hybrid-closed-loop-systems-in-clinical-practice-among-adults-living-with-type-1-diabetes
#5
JOURNAL ARTICLE
Ramanjit Singh, Henrik Imberg, Shilan Seyed Ahmadi, Sara Hallström, Johan Jendle, Bengt-Olov Tengmark, Anna Folino, Ekström Marie, Marcus Lind
BACKGROUND: There are few studies providing a more comprehensive picture of advanced hybrid closed-loop (AHCL) systems in clinical practice. The aim was to evaluate the effects of the AHCL systems, Tandem® t: slim X2™ with Control IQ™, and MiniMed™ 780G, on glucose control, safety, treatment satisfaction, and practical barriers for individuals with type 1 diabetes. METHOD: One hundred forty-two randomly selected adults with type 1 diabetes at six diabetes outpatient clinics in Sweden at any time treated with either the Tandem Control IQ (TCIQ) or the MiniMed 780G system were included...
April 17, 2024: Journal of Diabetes Science and Technology
https://read.qxmd.com/read/38629164/pilot-study-on-the-impact-of-early-subcutaneous-basal-insulin-administration-in-diabetic-ketoacidosis
#6
JOURNAL ARTICLE
Danielle S Murray, Brian W Gilbert, Tessa R Cox
Purpose/Background: Recent studies have shown improved outcomes with the initiation of earlier subcutaneous (SQ) basal insulin. The purpose of this study was to examine the effects of early SQ basal insulin administration on hospital length of stay in patients with mild to moderate diabetic ketoacidosis (DKA). Methods: This was a retrospective, single-center study from a large community teaching hospital that included patients 18 years or older with mild to moderate DKA, identified using ICD-10 codes, who received intravenous (IV) insulin...
April 17, 2024: Journal of Intensive Care Medicine
https://read.qxmd.com/read/38627464/ppar-agonists-as-add-on-treatment-with-metformin-in-management-of-type-2-diabetes-a-systematic-review-and-meta-analysis
#7
JOURNAL ARTICLE
Saif Alnuaimi, Tea Reljic, Fatima S Abdulla, Hamda Memon, Sarah Al-Ali, Teagen Smith, Fadila Serdarevic, Zelija Velija Asimi, Ambuj Kumar, Sabina Semiz
The combination of metformin and the peroxisome proliferator-activated receptors (PPAR) agonists offers a promising avenue for managing type 2 diabetes (T2D) through their potential complementary mechanisms of action. The results from randomized controlled trials (RCT) assessing the efficacy of PPAR agonists plus metformin versus metformin alone in T2D are inconsistent, which prompted the conduct of the systematic review and meta-analysis. We searched MEDLINE and EMBASE from inception (1966) to March 2023 to identify all RCTs comparing any PPAR agonists plus metformin versus metformin alone in T2D...
April 16, 2024: Scientific Reports
https://read.qxmd.com/read/38626972/cardiovascular-safety-of-evogliptin-dual-and-triple-therapy-in-patients-with-type-2-diabetes-a-nationwide-cohort-study
#8
JOURNAL ARTICLE
Sohee Park, Han Eol Jeong, In-Sun Oh, Sangmo Hong, Sung Hoon Yu, Chang Beom Lee, Ju-Young Shin
OBJECTIVE: To investigate the risk of cardiovascular events associated with commonly used dual and triple therapies of evogliptin, a recently introduced dipeptidyl peptidase-4 inhibitor (DPP4i), for managing type 2 diabetes in routine clinical practice. DESIGN: A retrospective cohort study. SETTING: Korean Health Insurance Review and Assessment database. PARTICIPANTS: Patients who initiated metformin-based dual therapy and metformin+sulfonylurea-based triple therapy in South Korea from 2014 to 2018...
April 15, 2024: BMJ Open
https://read.qxmd.com/read/38626447/obstetric-complications-and-birth-outcomes-after-antenatal-coronavirus-disease-2019-covid-19-vaccination
#9
JOURNAL ARTICLE
Kimberly K Vesco, Anna E Denoble, Heather S Lipkind, Elyse O Kharbanda, Malini B DeSilva, Matthew F Daley, Darios Getahun, Ousseny Zerbo, Allison L Naleway, Lisa Jackson, Joshua T B Williams, Thomas G Boyce, Candace C Fuller, Eric S Weintraub, Gabriela Vazquez-Benitez
OBJECTIVE: To evaluate the association between antenatal messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccination and risk of adverse pregnancy outcomes. METHODS: This was a retrospective cohort study of individuals with singleton pregnancies with live deliveries between June 1, 2021, and January 31, 2022, with data available from eight integrated health care systems in the Vaccine Safety Datalink. Vaccine exposure was defined as receipt of one or two mRNA COVID-19 vaccine doses (primary series) during pregnancy...
April 17, 2024: Obstetrics and Gynecology
https://read.qxmd.com/read/38623181/safety-and-efficacy-of-semaglutide-in-post-kidney-transplant-patients-with-type-2-diabetes-or-post-transplant-diabetes
#10
JOURNAL ARTICLE
Moeber Mohammed Mahzari, Omar Buraykan Alluhayyan, Mahdi Hamad Almutairi, Mohammed Abdullah Bayounis, Yazeed Hasan Alrayani, Amir A Omair, Awad Saad Alshahrani
OBJECTIVE: Type 2 diabetes mellitus (T2DM) and post-transplant diabetes mellitus (PTDM) are common in renal transplant recipients. Semaglutide has demonstrated efficacy and safety in patients with T2DM. To date, only a limited number of studies have investigated its use in renal transplant patients. This study assessed the safety and efficacy of semaglutide in post-renal transplant patients. METHODS: A retrospective study was conducted at king Abdulaziz Medical City-Riyadh, Saudi Arabia...
June 2024: Journal of Clinical & Translational Endocrinology
https://read.qxmd.com/read/38622856/aflibercept-vs-dexamethasone-implant-for-recalcitrant-diabetic-macular-edema-in-pseudophakic-eyes-1-year-outcomes-from-a-quazi-randomized-study-in-india
#11
JOURNAL ARTICLE
Debdulal Chakraborty, Soumen Mondal, Sabyasachi Sengupta, Aniruddha Maiti, Subhendu Boral, Arnab Das, Tushar K Sinha, Krishnendu Nandi
PURPOSE: To assess the safety and efficacy of intravitreal Aflibercept (IVA) versus dexamethasone (DEX) implant for treating recalcitrant diabetic macular edema (DME) in pseudophakic eyes at 1-year follow-up. DESIGN: Retrospective comparative case series. PARTICIPANTS: Data of all patients diagnosed with DME between January 2019 and December 2021, who underwent 4-monthly doses of intravitreal ranibizumab but had persistent DME [central macular thickness (CMT) within 10% of baseline value] were extracted from a computerized database...
April 16, 2024: Indian Journal of Ophthalmology
https://read.qxmd.com/read/38622453/long-term-treatment-of-hereditary-transthyretin-amyloidosis-with-patisiran-multicentre-real-world-experience-in-italy
#12
JOURNAL ARTICLE
Luca Gentile, Anna Mazzeo, Chiara Briani, Silvia Casagrande, Marcella De Luca, Gian Maria Fabrizi, Christian Gagliardi, Chiara Gemelli, Francesca Forcina, Marina Grandis, Valeria Guglielmino, Giacomo Iabichella, Luca Leonardi, Alessandro Lozza, Fiore Manganelli, Roberta Mussinelli, Filomena My, Giuseppe Occhipinti, Silvia Fenu, Massimo Russo, Angela Romano, Alessandro Salvalaggio, Matteo Tagliapietra, Stefano Tozza, Giovanni Palladini, Laura Obici, Marco Luigetti
BACKGROUND: Hereditary transthyretin (ATTRv, v for variant) amyloidosis with polyneuropathy is a rare disease caused by mutations in the transthyretin gene. In ATTRv amyloidosis, multisystem extracellular deposits of amyloid cause tissue and organ dysfunction. Patisiran is a small interfering RNA molecule drug that reduces circulating levels of mutant and wild-type TTR proteins. Prior to its regulatory approval, patisiran was available in Italy through a compassionate use programme (CUP)...
April 16, 2024: Neurological Sciences
https://read.qxmd.com/read/38618974/the-effect-of-renal-function-on-the-pharmacokinetics-and-pharmacodynamics-of-enavogliflozin-a-potent-and-selective-sodium-glucose-cotransporter-2-inhibitor-in-type-2-diabetes
#13
JOURNAL ARTICLE
Sae Im Jeong, Mu Seong Ban, Jun-Gi Hwang, Min-Kyu Park, Soo Lim, Sejoong Kim, Soon Kil Kwon, Yoonjin Kim, Jae Min Cho, Jae Jin Na, Wan Huh, Jae-Yong Chung
AIMS: To explore the effect of renal function on the pharmacokinetic (PK) and pharmacodynamic (PD) profile and safety of enavogliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes mellitus (T2DM). METHODS: An open-label, two-part clinical trial was conducted in T2DM patients, stratified by renal function: Group 1, normal renal function; Group 2, mild renal impairment (RI); Group 3, moderate RI; and Group 4, severe RI...
April 15, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38618970/combination-of-retagliptin-and-henagliflozin-as-add-on-therapy-to-metformin-in-patients-with-type-2-diabetes-inadequately-controlled-with-metformin-a-multicentre-randomized-double-blind-active-controlled-phase-3-trial
#14
JOURNAL ARTICLE
Yao Wang, Chengxia Jiang, Xiaolin Dong, Mingwei Chen, Qin Gu, Lihui Zhang, Yanqin Fu, Tianrong Pan, Yan Bi, Weihong Song, Jing Xu, WeiPing Lu, Xiaodong Sun, Zi Ye, Danli Zhang, Liang Peng, Xiang Lin, Wei Dai, Quanren Wang, Wenying Yang
AIM: This study assessed the efficacy and safety of co-administering retagliptin and henagliflozin versus individual agents at corresponding doses in patients with type 2 diabetes mellitus who were inadequately controlled with metformin. METHODS: This multicentre, phase 3 trial consisted of a 24-week, randomized, double-blind, active-controlled period. Patients with glycated haemoglobin (HbA1c) levels between 7.5% and 10.5% were randomized to receive once-daily retagliptin 100 mg (R100; n = 155), henagliflozin 5 mg (H5; n = 156), henagliflozin 10 mg (H10; n = 156), co-administered R100/H5 (n = 155), or R100/H10 (n = 156)...
April 15, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38617770/comparison-of-safety-and-effectiveness-of-different-sheaths-in-ablation-of-focal-atrial-tachycardia-a-retrospective-study
#15
JOURNAL ARTICLE
Min Xie, Dingming Liu, Ruikun Jia, Yixuan Bai, Juan Chan, Zhongyun Lin, Paul Khairy, Kaijun Cui
BACKGROUND: A novel visualized steerable sheath, referred to as the Vizigo sheath, has been utilized in clinical interventions. The objective of this study was to evaluate and contrast the efficacy and safety of the Vizigo sheath with other sheaths in the catheter ablation (CA) for focal atrial tachycardia (FAT). METHODS: A retrospective cohort study was conducted on consecutive patients with CA for FAT from March 2019 to February 2022. Objectives were to assess the impact of the Vizigo sheath on acute and long-term ablation success rates, procedural and fluoroscopy times, and contact force (CF)...
March 29, 2024: Journal of Thoracic Disease
https://read.qxmd.com/read/38610878/pharmacological-and-benefit-risk-profile-of-once-weekly-basal-insulin-administration-icodec-addressing-patients-unmet-needs-and-exploring-future-applications
#16
REVIEW
Ylenia Ingrasciotta, Giacomo Vitturi, Gianluca Trifirò
Diabetes mellitus (DM) is a chronic metabolic disease affecting over 500 million people worldwide, which leads to severe complications and to millions of deaths yearly. When therapeutic goals are not reached with diet, physical activity, or non-insulin drugs, starting/adding insulin treatment is recommended by international guidelines. A novel recombinant insulin is icodec, a once-weekly insulin that successfully completed phase III trials and that has recently obtained the marketing authorization approval from the European Medicines Agency...
April 5, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38610175/harnessing-the-synergy-of-sglt2-inhibitors-and-continuous-ketone-monitoring-ckm-in-managing-heart-failure-among-patients-with-type-1-diabetes
#17
REVIEW
Nicola Tecce, Giorgio de Alteriis, Giulia de Alteriis, Ludovica Verde, Mario Felice Tecce, Annamaria Colao, Giovanna Muscogiuri
Heart failure (HF) management in type 1 diabetes (T1D) is particularly challenging due to its increased prevalence and the associated risks of hospitalization and mortality, driven by diabetic cardiomyopathy. Sodium-glucose cotransporter-2 inhibitors (SGLT2-is) offer a promising avenue for treating HF, specifically the preserved ejection fraction variant most common in T1D, but their utility is hampered by the risk of euglycemic diabetic ketoacidosis (DKA). This review investigates the potential of SGLT2-is in T1D HF management alongside emergent Continuous Ketone Monitoring (CKM) technology as a means to mitigate DKA risk through a comprehensive analysis of clinical trials, observational studies, and reviews...
March 29, 2024: Healthcare (Basel, Switzerland)
https://read.qxmd.com/read/38608426/efficacy-and-safety-evaluation-of-energy-devices-in-bench-surgery-for-pancreas-transplantation
#18
JOURNAL ARTICLE
Keizo Kaku, Shinsuke Kubo, Yu Sato, Takanori Mei, Hiroshi Noguchi, Yasuhiro Okabe, Masafumi Nakamura
INTRODUCTION: Bench surgery for the preparation of deceased donor pancreatic grafts is labor-intensive and time-consuming. We hypothesized that energy devices could be used during bench surgery to decrease the bench surgery time. However, because bench surgery has two unique characteristics, wet conditions and no blood flow in the vessels, it is necessary to verify the safety and efficacy under such conditions. METHODS: In an animal tissue model, we validated both ultrasonic and bipolar energy devices: Harmonic Shears and the LigaSure (LS) vessel-sealing device by evaluating heat spread and pressure resistance under bench surgery conditions...
April 11, 2024: Journal of Surgical Research
https://read.qxmd.com/read/38607214/uterine-artery-doppler-parameters-an-excellent-tool-for-assessing-adverse-pregnancy-outcomes
#19
JOURNAL ARTICLE
Minsui Cai, Yan Lu, Ying Li, Qi Cui
OBJECTIVE: ObjectiveThis study aims to assess the utility of uterine artery Doppler parameters in predicting adverse pregnancy outcomes among pregnant women, thereby enhancing the safety of pregnancy. METHODS: This study utilized a prospective observational design. A total of 142 pregnant women who underwent prenatal ultrasonography at our hospital and Wuxi Maternal and Child Health Hospital (Maternity Hospital affiliated with Jiangnan University) from May 2022 to May 2023 were included...
April 12, 2024: Alternative Therapies in Health and Medicine
https://read.qxmd.com/read/38605888/preparation-of-ha-mao-coatings-on-%C3%AE-type-alloys-and-its-corrosion-resistance-in-high-glucose-environments
#20
JOURNAL ARTICLE
Dong Li, Zhuan Zou, Xiaoyun Qiu, Mingyue Zhu, Xiaolian Zhao, Shengyuan Lei, Quanzhi Chen
Aim to provide practical clinical guidance for the treatment of implants in diabetic patients, this study investigated the corrosion mechanism of bionic coatings containing different Ca/P ratios in diabetic environments. The bionic coatings were prepared in β-titanium alloys using micro-arc oxidation (MAO) technology and evaluated for corrosion mechanism, biocompatibility, and safety by cytotoxicity, electrochemical corrosion, and coating bonding force experiments. Ca and P from the electrolyte were integrated into the coating during MAO discharge process to form hydroxyapatite...
April 10, 2024: RSC Advances
keyword
keyword
105285
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.